Radiation and new drug combo tested to fight spreading cancers
NCT ID NCT04785287
Summary
This early-phase trial tested the safety and initial effectiveness of a new immunotherapy drug (BMS-986218), given alone or with another immunotherapy drug (nivolumab), alongside targeted radiation therapy. It was for adults with advanced solid cancers that had spread to other parts of the body, such as the lung, liver, or adrenal glands. The goal was to see if this combination could help the immune system attack cancer cells more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.